Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 102

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part II, Item 1A
Chunk 102
---
 to essential proprietary
technologies, such as Aquanova’s NovaSOL® formulation technology, which is critical for the bioavailability and effectiveness
of our Nugevia brand. Disputes over contract terms, intellectual property rights, or performance obligations could result in costly litigation,
delays in product development, or loss of commercialization rights. Additionally, our obligation to pay license fees and royalties under
the license agreement represents a significant financial commitment, and any inability to meet these obligations could jeopardize our
rights under the license agreement. The loss or impairment of this license would require us to seek alternative technologies or partners,
which may not be available on favorable terms, if at all, and could delay or prevent the development and commercialization of our products.

Should
we fail to maintain a productive relationship with Aquanova or if Aquanova experiences operational or financial difficulties, our ability
to deliver products to market could be compromised, negatively impacting our growth prospects and competitive position.

If
the Company or its suppliers fails to comply with FDA or other regulations, it could result in enforcement actions or delays in the Nugevia
brand product launch.

The
Company is subject to various federal, state, and local laws, regulations and administrative practices that affect its business. Our
suppliers and contract manufacturers are also subject to such laws and regulations. The safety, formulation, manufacturing, processing,
packaging, importation, labeling, promotion, advertising, and distribution of the Nugevia brand products are subject to regulation by
several federal agencies, including the FDA, the FTC, the USDA, the CPSC and the EPA, as well as by various state and local agencies.
If these laws and regulations were violated by our management, suppliers or distributors, we could be subject to regulatory enforcement
action, public warning letters, product recalls, fines, penalties and sanctions, including injunctions against the future shipment and
sale of products, restitution and disgorgement of profits, operating restrictions. In addition, other public and private actors are increasingly
targeting supplement retailers and manufacturers with class action lawsuits for selling products that allegedly fail to adhere to the
requirements of FDCA, DSHEA, and other federal and state statutes and requirements, including for failing to adhere to current GPMs,
making false or misleading product statements, providing inaccurate ingredient identity and potency, and failing to control or disclose
allergens, contaminants, residues and adulterants, as well as for state common and statutory laws regarding deceptive trade practices.

We
could also be